AstraZeneca, Oxford Biomedica expand COVID-19 vaccine supply tie-up

iStock [illustration]

AstraZeneca has expanded its previous agreement with Oxford Biomedica to mass-produce the British drugmaker's COVID-19 vaccine candidate.

It comes as the firm looks to scale-up supply ahead of a possible fast-track approval from the United States.

Gene and cell therapy firm Oxford Biomedica said on Tuesday AstraZeneca would give it $15 million upfront to reserve manufacturing capacity at its plant and that it could get an additional $35 million-plus other costs until the end of 2021 under the new 18-month deal.

AstraZeneca's vaccine hopeful for the novel coronavirus, AZD1222, already among the leading candidates in the global race for the successful vaccine, moved to late-stage trials in the US this week as the company targets 3 billion doses of the vaccine.

Oxford Biomedica was among AstraZeneca's initial partners when they teamed up in May to produce the vaccine and Tuesday's deal could be further expanded by another year and a half into 2022 and 2023, Oxford said.

More from International

Coming Up on Dubai Eye

  • Extra Time

    7:00pm - 8:00pm

    Chris & Robbie bring you the latest from the sporting world plus interviews with upcoming and legendary sporting stars.

  • The Night Shift with Mark Lloyd

    8:00pm - 10:00pm

    Musicians and music, entertainers and entertainment, industry gossip and songs selected by you, get ready to bring your night time to life! Every evening from nine, Mark Lloyd brings you an energetic mix of local and international content and contests, featuring an array of celebrity interviews and entertaining anecdotes. Get involved in the show and pick your favourite jukebox hits, every night from 8pm - 11pm.

On Dubai Eye

Business Breakfast